全球生物治疗药物的负担能力前景
Anurag S Rathore1, Peter J Gardner2, Hemlata Chhabra1
1Department of Chemical Engineering, Indian Institute of Technology, Delhi, India.
Annals of the New York Academy of Sciences
|June 14, 2024
概括
生物治疗药物的负担能力在低收入国家最低,预计到2040年,在中等收入国家会显著恶化. 需要采取紧急措施,在全球范围内改善获得这些救命药物的机会.
科学领域:
- 药物经济学 药物经济学
- 全球卫生政策 全球卫生政策
- 生物制药接入 生物制药接入
背景情况:
- 生物治疗药物为治疗严重疾病提供了变革性的潜力.
- 然而,关于它们的全球负担能力和可访问性,仍然存在重大挑战.
- 这种差异影响了患者的结果,特别是在低收入环境中.
研究的目的:
- 为全球生物治疗产品的可负担性提供全面的概述.
- 分析不同收入水平国家的价格变化.
- 根据经济指标预测未来的可负担性趋势.
主要方法:
- 研究了40个国家的10种代表性生物治疗产品的价格.
- 分类国家为高收入 (HICs),高中收入 (UMICs),低中收入 (LMICs) 和低收入 (LICs).
- 使用世界卫生组织/国际卫生行动 (WHO/HAI) 方法计算了可负担性.
主要成果:
- 生物治疗性负担能力在HIC中最高,其次是UMIC,LMIC和LIC.
- 预测显示,UMICs (1.5x到2030年,4x到2040年) 和LMICs (2x到2030年,6x到2040年) 的负担能力正在恶化.
- 预计在未来几十年内,HIC的可负担性将保持相对稳定.
结论:
- 立即干预对于提高生物治疗药物的可负担性和可获得性至关重要.
- 政府应实施支持性政策,以促进访问.
- 全球卫生组织和制造商必须在创新解决方案和制造业进步方面进行合作.
相关概念视频
Bioequivalence: Overview
991
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
991
Bioavailability: Overview
2.8K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.8K
Factors Influencing Bioavailability: First-Pass Elimination
6.3K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.3K
Drug Control Governance: Regulatory Bodies and Their Impact
150
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
150
Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K


